IMVARIA is a health‑tech company (Software-as-Medical-Device) pioneering AI-driven digital biomarker solutions to help clinicians diagnose and prognose disease non‑invasively and earlier. Founded in 2019 by physician‑engineers from Google and Stanford, the company is based in Berkeley, CA, and focuses initially on lung disease.

IMVARIA operates a centralized cloud "AI Lab" that analyzes clinical testing and imaging (for example, chest CT) to generate AI-driven diagnostic and screening outputs. Principal products include Fibresolve (FDA-authorized adjunctive diagnostic for idiopathic pulmonary fibrosis), ScreenDx (FDA 510(k) clearance for incidental detection/assessment of interstitial lung disease), and Bronchosolve (investigational lung nodule assessment).

IMVARIA is a remote-first company hiring engineering and commercial teams; open roles are posted on Wellfound. General contact: [email protected]; headquarters: Berkeley, CA.